Every 424B that Veru Inc. (VERU) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow VERU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VERU filings page.
Veru Inc. registered an at-the-market offering to sell up to $21,800,000 of its common stock pursuant to a Sales Agreement dated July 2, 2026 with Oppenheimer & Co. Inc. and Canaccord Genuity LLC.
The offering is being made under the company’s Form S-3 shelf (total capacity $200,000,000) and shares may be sold from time to time at market prices. The prospectus supplement states the shares may be sold through the designated Sales Agent as agent or principal and that the Sales Agents’ commission is 3.0% of gross proceeds. The company intends to use net proceeds for general corporate purposes. The offering size is subject to the Form S-3 instruction limiting sales to one-third of public float while public float remains below $75.0 million.
Veru Inc. launched a primary offering of 1,400,000 shares of common stock and pre-funded warrants to purchase up to 7,000,000 shares, together with Series A warrants to purchase up to 8,400,000 shares and Series B warrants to purchase up to 8,400,000 shares. The combined public offering price is $3.00 per share with warrants (or $2.999 with a pre-funded warrant).
Pre-funded warrants are immediately exercisable at $0.001 per share. Series A and Series B warrants are immediately exercisable at $3.00 per share; Series A expire five years from issuance. Series B expire on the earlier of the third anniversary or 45 days after specified clinical and stock-price conditions are met. The company does not intend to list the warrants.
Veru estimates net proceeds of approximately $23.4 million, to fund development of enobosarm, primarily the planned Phase 2b PLATEAU obesity study, and for working capital and general corporate purposes. Shares outstanding were 14,650,392 as of June 30, 2025; this is a baseline figure, not the amount being offered.
Veru Inc. filed a preliminary prospectus supplement for a primary offering of common stock and, in lieu of shares for certain investors, pre-funded warrants, together with accompanying Series A and Series B common stock warrants. The filing also covers the shares issuable upon exercise of these warrants.
The company states it will receive the proceeds from this offering and intends to use them primarily to fund the planned Phase 2b PLATEAU clinical study of enobosarm in combination with GLP‑1 RA therapy, as well as for working capital and general corporate purposes. Pre-funded warrants are immediately exercisable at $0.001 per share. Series A warrants are immediately exercisable and expire five years from issuance. Series B warrants are immediately exercisable and expire on the earlier of a data/price milestone or three years. The warrants will not be listed, which may limit liquidity.
Shares outstanding were 14,650,392 as of June 30, 2025. The company effected a 1‑for‑10 reverse stock split on August 8, 2025. Veru’s common stock last closed at $3.65 on October 28, 2025.